Ingredient Guide
Akkermansia muciniphila: Benefits, Dosage, and What the Research Says
The mucus-layer microbe at the center of metabolic health research
Written by Jessica Medson
Akkermansia muciniphila is a naturally occurring gut bacterium that resides in the intestinal mucus layer and, in healthy adults, accounts for roughly 1 to 4 percent of the total gut microbiome. Lower abundance of this bacterium has been associated in observational studies with obesity, insulin resistance, and type 2 diabetes. The most rigorous human trial to date — a randomized, double-blind, placebo-controlled pilot study published in Nature Medicine — found that daily supplementation with pasteurized A. muciniphila for three months improved insulin sensitivity by approximately 29% and reduced total cholesterol by nearly 9% compared to placebo in overweight insulin-resistant adults; however, this trial enrolled only 32 participants and the field still needs larger confirmatory studies before firm efficacy conclusions can be drawn.
What Is Akkermansia muciniphila?
Akkermansia muciniphila is a Gram-negative, strictly anaerobic bacterium that inhabits the mucous layer lining the human large intestine. It was first characterized in 2004 by Derrien and colleagues at Wageningen University, who isolated it from healthy human feces and named it for its defining trait: the ability to degrade mucin, the glycoprotein backbone of intestinal mucus.1
In healthy adults, A. muciniphila typically accounts for 1 to 4 percent of the intestinal microbiome, placing it among the more abundant single bacterial species in the colon. Phylogenetically, it belongs to the phylum Verrucomicrobia — a lineage entirely distinct from the Firmicutes and Bacteroidetes that dominate most gut microbiome research, and the only gut-resident member of its phylum with well-established health associations.
How do gut levels relate to health?
Multiple observational studies have linked lower-than-normal A. muciniphila abundance to several metabolic and inflammatory conditions. In a metagenomic analysis of 182 lean and obese individuals, reduced A. muciniphila levels were found in lean participants with newly diagnosed type 2 diabetes compared to healthy controls, and correlated positively with markers of insulin secretion.5 Reduced abundance has also been reported in association with obesity, metabolic syndrome, and inflammatory bowel disease — though these are associations, not proven causal relationships.
- A. muciniphila is naturally present in the human gut from early in life and is considered part of a healthy core microbiome
- Levels appear to decline with aging, long-term high-fat diets, antibiotic exposure, and some chronic conditions
- It is often described as a "next-generation probiotic" due to evidence linking it to host metabolic health
- The European Food Safety Authority (EFSA) approved the pasteurized form as a novel food for adults in 2021, the first regulatory recognition of its kind13
How Does Akkermansia muciniphila Work?
Unlike conventional probiotics that primarily compete for colonization in the intestinal lumen, A. muciniphila operates directly within the mucus layer — a position that gives it unusual proximity to intestinal epithelial cells and immune signaling structures. Several distinct mechanisms have been identified in preclinical and early clinical research.
Mucin degradation and microbial cross-feeding
A. muciniphila uses mucin glycoproteins as its primary carbon and nitrogen source. This degradation releases acetate and propionate, which serve as energy substrates for butyrate-producing bacteria such as Clostridia species — a form of microbial cross-feeding that may help sustain a diverse, balanced gut community. Mouse studies suggest that mucin breakdown by A. muciniphila simultaneously stimulates the host to produce more mucin, compensatorily maintaining mucus layer thickness through a feedback loop.2
The Amuc_1100 outer membrane protein and TLR2 signaling
A landmark study published in Nature Medicine (2017) identified Amuc_1100, a specific outer membrane protein of A. muciniphila that interacts with Toll-like receptor 2 (TLR2) on intestinal epithelial cells.3 In obese and diabetic mouse models, administering either pasteurized A. muciniphila or purified Amuc_1100 strengthened the gut barrier, reduced translocation of endotoxin (lipopolysaccharide, LPS) into the bloodstream, and improved metabolic markers. Critically, Amuc_1100 is heat-stable — it retains its activity after pasteurization — which likely explains why the pasteurized form has matched or outperformed live bacteria on metabolic endpoints in direct comparisons.
GLP-1 stimulation via the P9 secreted protein
Research published in Nature Microbiology (2021) identified a secreted 84 kDa protein designated P9, produced by A. muciniphila, that binds to intercellular adhesion molecule-2 (ICAM-2) on intestinal L cells and stimulates glucagon-like peptide-1 (GLP-1) secretion.4 In high-fat-diet mouse models, P9 reduced body weight gain, improved glucose tolerance, and enhanced thermogenesis in brown adipose tissue. This mechanism has not yet been confirmed in human studies and should be considered Tier C (preclinical) evidence until human data emerge.
Tight junction upregulation
Both the intact bacterium and isolated Amuc_1100 have been shown in preclinical models to increase expression of tight junction proteins — including claudin-3, occludin, and ZO-1 — that seal the spaces between intestinal epithelial cells.9 Restoring these proteins is associated with reduced permeability to microbial products and decreased downstream inflammatory signaling. A 2024 review synthesizing the full mechanistic landscape also highlighted A. muciniphila's potential relevance to oncology and neurology through gut-brain axis interactions, though human evidence for those applications is very preliminary.12
Metabolic Health: Insulin Sensitivity, Body Weight, and Cholesterol
The most-studied clinical application of A. muciniphila supplementation is metabolic health — specifically, effects on insulin sensitivity, body weight, and blood lipids. Human evidence is growing but remains limited by small trial sizes and the finding that responses appear to depend substantially on an individual's baseline gut levels of the bacterium.
What the research shows
2019 proof-of-concept RCT (Nature Medicine, n=32). In the most cited human intervention to date, 32 overweight or obese insulin-resistant adults completed a randomized, double-blind, placebo-controlled trial receiving 1010 cells per day of either pasteurized A. muciniphila, live A. muciniphila, or placebo for three months.6 Compared to placebo, pasteurized supplementation was associated with:
- A 28.6% improvement in insulin sensitivity (P = 0.002)
- A 34.1% decrease in insulinemia (P = 0.006)
- An 8.7% reduction in total plasma cholesterol (P = 0.02)
- Approximately 2.3 kg less body weight versus placebo
- Improved blood markers of liver dysfunction and inflammation
The supplementation was rated safe and well tolerated throughout. Notably, pasteurized A. muciniphila outperformed live bacteria on most metabolic endpoints. This is a meaningful finding, but the pilot scale (32 completers) means results require confirmation in larger trials.
2025 type 2 diabetes RCT (Cell Metabolism, n=58). A 12-week double-blind, placebo-controlled trial in overweight and obese adults with type 2 diabetes did not find significant between-group differences in body weight or HbA1c across the full study population.7 However, in participants with low baseline A. muciniphila levels, those randomized to supplementation showed significant reductions in body weight, fat mass, and HbA1c not seen in placebo recipients. Participants with high baseline levels showed poor colonization and no measurable benefit — a pattern the authors describe as baseline-dependent efficacy, suggesting microbiome testing may eventually inform whether a given individual is likely to respond.
2026 metabolic syndrome RCT (Gut Microbes, n=142). A multicenter, double-blind, placebo-controlled trial in 142 adults with metabolic syndrome administered daily pasteurized A. muciniphila for four months.8 The primary endpoint — whole-body insulin sensitivity (Matsuda index) in the intention-to-treat population — was not significantly different from placebo. Exploratory analyses of the low-baseline-Akkermansia subgroup showed improved insulin sensitivity, improved post-meal GLP-1 response, and reduced trunk fat (P < 0.05). Prediabetic participants and those aged 63 or older showed improved hepatic insulin sensitivity at the 3-month mark.
Preclinical data support the direction of these human findings: a 2024 meta-analysis of 15 animal studies found that A. muciniphila supplementation was associated with a 10.4% reduction in body weight gain, a 21.2% decrease in fasting blood glucose, and a 22.1% improvement in glucose tolerance on average.10 Animal-to-human translation is uncertain, and these figures should be interpreted accordingly.
Gut Barrier Integrity and Systemic Inflammation
Beyond its metabolic effects, A. muciniphila research suggests it may help maintain the physical and immunological integrity of the gut lining — a property that may, in fact, underlie many of its metabolic associations.
What the research shows
The intestinal mucus layer acts as a physical buffer between the gut microbiome and the epithelial cells lining the intestinal wall. When this layer thins or becomes compromised, bacterial-derived molecules such as LPS can cross into the bloodstream, triggering low-grade systemic inflammation known as metabolic endotoxemia. In mouse models of high-fat-diet-induced obesity, restoring A. muciniphila levels reversed markers of increased gut permeability, reduced circulating endotoxin, and attenuated adipose tissue inflammation.2
The bacterium's Amuc_1100 protein upregulates tight junction proteins (claudin-3, occludin, ZO-1) and activates anti-inflammatory signaling through TLR2 — a pathway distinct from the pro-inflammatory TLR4 cascade that LPS activates.3 This mechanistic specificity has drawn significant scientific interest. A 2024 review characterizing the full scope of barrier-function evidence concluded that A. muciniphila strengthens intestinal barrier integrity through goblet cell stimulation, tight junction upregulation, SCFA production, and immune modulation, and described it as a promising therapy candidate for intestinal diseases.9
In the 2019 human pilot trial, participants receiving pasteurized supplementation showed improvements in blood markers associated with liver inflammation — consistent with reduced endotoxin translocation, though gut permeability itself was not directly measured.6 Human-specific evidence for barrier enhancement therefore remains indirect; most mechanistic data are Tier C (animal and cell culture).
Research in inflammatory bowel disease is exploratory. Reduced A. muciniphila levels have been documented in people with Crohn's disease and ulcerative colitis, and preclinical data suggest restoration may reduce intestinal inflammation.11 An important caveat, however: in IL-10-deficient mice (an immune dysregulation model), repeated oral supplementation promoted rather than reduced intestinal inflammation — a clear signal that the bacterium's effects depend on the host's immune context, and that IBD patients in particular should not self-supplement without medical guidance.11 Human trials in IBD have not yet been completed.
Safety, Side Effects, and Interactions
The safety profile of Akkermansia muciniphila has been formally evaluated in human clinical trials and in a regulatory safety opinion. Overall, short-term supplementation with pasteurized A. muciniphila in healthy overweight adults appears safe and well tolerated, but several important qualifications apply.
Human trial safety findings
In the 2019 Nature Medicine pilot trial, three months of daily supplementation with pasteurized A. muciniphila (1010 cells per day) produced no serious adverse events attributed to the intervention.6 Gastrointestinal complaints — primarily transient bloating or loose stools — are the most commonly reported side effects across published studies and occur at rates similar to placebo in available trials.
EFSA safety review (2021)
Following a formal application, the European Food Safety Authority concluded in 2021 that pasteurized A. muciniphila is safe for adult use at up to approximately 3.4 x 1010 cells per day, provided viable (live) cell counts in the finished product remain below 10 CFU/g.13 Safety conclusions were based on a 90-day rat toxicology study with an uncertainty factor applied to establish the human safe dose. Nutritional disadvantage was not observed at proposed use levels.
Contraindications and special populations
- Pregnancy and breastfeeding: EFSA explicitly excluded pregnant and lactating women from its approval; no adequate safety data are available for these populations. Supplementation is not recommended.
- Immunocompromised individuals: As with any microbiome-modifying supplement, people receiving immunosuppressive therapy, those with active IBD flares, or those otherwise immunocompromised should consult a healthcare provider before use. Preclinical data show that immune context can reverse the bacterium's typical effects, converting anti-inflammatory activity to pro-inflammatory.11
- Children under 12: EFSA's original approval covers adults only. An extension to adolescents ages 12 to 17 is under regulatory review as of 2025; use in younger children is not supported by available evidence.13
Potential drug interactions
No specific drug interactions have been documented in published human trials. Because research suggests A. muciniphila may influence insulin sensitivity and GLP-1 signaling,64 individuals using medications for blood sugar management — including metformin, GLP-1 receptor agonists, or insulin — should discuss supplementation with their prescriber. Antibiotic courses are likely to reduce colonization efficacy of live-form products; timing supplementation around antibiotic use is advisable.
Live vs. pasteurized formulations
Most commercially available A. muciniphila supplements use the pasteurized (heat-killed, postbiotic) form. Current trial data suggest this form is at least as effective as live bacteria for metabolic endpoints — likely because the key active protein Amuc_1100 survives pasteurization intact. The pasteurized form also carries EFSA novel-food approval; the live form lacks an equivalent regulatory endorsement for supplement use. When evaluating a product, look for the cell count per serving expressed in CFU or cells, and verify the form (live vs. pasteurized) on the label.
Akkermansia muciniphila Dosage Guide
The following doses reflect those used in published human clinical trials and the regulatory safe-use level established by EFSA. Individual supplement products vary; follow the label and consult a healthcare provider for personalized guidance.
| Goal | Typical Dose | Timing | Notes |
|---|---|---|---|
| General gut microbiome support | 10 billion cells (10^10) per day, pasteurized form | Once daily, with or without food | Dose used in the 2019 Nature Medicine pilot RCT; consistent with most commercial pasteurized products |
| Metabolic health support (insulin sensitivity, body composition) | 10 billion cells (10^10) per day, pasteurized form | Daily for at least 3 months; shorter courses have not been well studied | Based on 3-month human trial data. Benefits appear most pronounced in individuals with low baseline gut Akkermansia levels |
| Regulatory maximum (EFSA, adults) | Up to 3.4 x 10^10 cells per day, pasteurized form | Daily | EFSA safe-use ceiling based on 90-day toxicology data; approved for adults only, excluding pregnant and lactating women |
No human dosing data exist for live-form (probiotic) A. muciniphila in well-controlled RCTs; efficacy data largely derive from pasteurized (postbiotic) formulations. Higher doses have not been shown to confer greater benefit.
What the Evidence Shows at a Glance
Summary of key outcomes studied in Akkermansia muciniphila research, with evidence classification. Tier A = human RCT or meta-analysis of RCTs; Tier B = human observational; Tier C = animal or cell-culture only.
| Outcome | What studies found | Evidence strength | Key caveat |
|---|---|---|---|
| Insulin sensitivity | ~29% improvement vs placebo over 3 months (pasteurized) | Tier A - small pilot RCT, n=32 | Trial was underpowered; not yet replicated at scale |
| Insulinemia | ~34% decrease vs placebo | Tier A - small pilot RCT, n=32 | Same single trial; needs confirmation |
| Total cholesterol | ~8.7% reduction vs placebo | Tier A - small pilot RCT, n=32 | Same single trial; no LDL/HDL breakdown reported |
| Body weight | ~2.3 kg less than placebo at 3 months | Tier A - small pilot RCT | Baseline-dependent; larger trials show mixed results |
| HbA1c in type 2 diabetes | Significant reductions in low-baseline-Akkermansia subgroup only | Tier A - RCT, n=58 | Overall intention-to-treat comparison not significant |
| Whole-body insulin sensitivity (metabolic syndrome) | Primary endpoint not met in 4-month multicenter RCT | Tier A - RCT, n=142 | Benefit seen only in low-baseline subgroups exploratorily |
| Gut barrier / tight junction proteins | Upregulation of claudin-3, occludin, ZO-1 in preclinical models | Tier C - animal and cell data | Human permeability measurements largely absent from trials |
| GLP-1 secretion | P9 protein stimulates GLP-1 in mouse intestinal L cells | Tier C - mouse data only | Not yet demonstrated in humans |
| Gut microbiome diversity | Lower A. muciniphila levels observed in obesity and T2DM vs healthy controls | Tier B - human observational | Correlation, not causation; confounders likely |
Evidence tiers reflect the design quality and population of the strongest available study for each outcome, not the totality of the literature.
Frequently Asked Questions
What is Akkermansia muciniphila good for?
Clinical research suggests Akkermansia muciniphila may help support insulin sensitivity, healthy body weight, and cholesterol levels in overweight adults with metabolic concerns. It also has mechanistic links to gut barrier integrity. Most evidence comes from small pilot trials; the bacterium appears most beneficial in people who already have low gut levels of it.
How much Akkermansia muciniphila should I take?
The dose used in the landmark 2019 human RCT was 10 billion cells (10^10) per day of pasteurized A. muciniphila for three months. The European Food Safety Authority has set a safe adult ceiling of approximately 3.4 x 10^10 cells per day. Follow your product label and consult a healthcare provider if you have underlying health conditions.
Is Akkermansia muciniphila safe?
In published human trials, pasteurized A. muciniphila was well tolerated with no serious adverse events at 10 billion cells per day for three months. EFSA approved it as a novel food for adults in 2021. Pregnant and breastfeeding women and immunocompromised individuals should consult a physician before use, as safety data for those groups are limited.
Does Akkermansia muciniphila help with weight loss?
Research suggests it may support healthy body composition in some people. In the main human pilot study, participants on pasteurized A. muciniphila lost roughly 2.3 kg more than placebo over three months. However, a larger 4-month multicenter trial did not find significant weight differences overall — benefit appeared mainly in participants with low baseline gut levels of the bacterium.
What are the side effects of Akkermansia muciniphila?
Reported side effects in human trials are mild and infrequent — primarily transient bloating or loose stools, occurring at rates similar to placebo. No serious adverse events have been attributed to pasteurized A. muciniphila supplements in published studies. As always, individuals with gut conditions, immune disorders, or who are pregnant should seek medical guidance first.
Is pasteurized Akkermansia muciniphila better than live?
Current evidence suggests the pasteurized (heat-killed) form is at least as effective as live bacteria for metabolic outcomes, and in the 2019 pilot RCT it slightly outperformed the live form. This is because a key active protein, Amuc_1100, is heat-stable and remains intact after pasteurization. The pasteurized form also has EFSA novel-food approval and is more shelf-stable.
How long does Akkermansia muciniphila take to work?
The primary human trial showing metabolic benefits ran for three months, and most measurable improvements appeared within that timeframe. Shorter courses have not been well studied in controlled trials. Effect timing may also depend on baseline gut levels — individuals with low starting levels appear to show higher colonization and faster measurable response.
Who should not take Akkermansia muciniphila?
Pregnant and breastfeeding women (excluded from EFSA's approval due to absent safety data), children under 12, and immunocompromised individuals should avoid supplementation without medical supervision. Preclinical data show the bacterium can promote intestinal inflammation in certain immune-dysregulation models, suggesting the effect is not universally beneficial.
Does Akkermansia muciniphila work for everyone?
No — current evidence strongly suggests responses are baseline-dependent. Two independent 2025-2026 clinical trials found that metabolic benefits were concentrated in participants with low initial gut levels of A. muciniphila. People who already have robust gut populations of the bacterium may see little or no additional benefit from supplementation.
What is the difference between a probiotic and a postbiotic Akkermansia supplement?
Live A. muciniphila products are classified as probiotics (viable organisms intended to colonize the gut). Pasteurized A. muciniphila is classified as a postbiotic (non-viable but bioactive). Most commercial Akkermansia products use the pasteurized postbiotic form, which has EFSA regulatory approval, is shelf-stable without refrigeration, and is backed by the stronger clinical trial data.
Shop Akkermansia muciniphila
HealthFare Akkermansia muciniphila supplements
Scientific References
- 1.Derrien M, Vaughan EE, Plugge CM, de Vos WM Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. International Journal of Systematic and Evolutionary Microbiology. 2004. PubMed: 15388697Preclinical (animal / cell)
- 2.Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proceedings of the National Academy of Sciences USA. 2013. PubMed: 23671105Preclinical (animal / cell)
- 3.Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nature Medicine. 2017. PubMed: 27892954Preclinical (animal / cell)
- 4.Yoon HS, Cho CH, Yun MS, Jang SJ, You HJ, Kim JH, Han D, Cha KH, Moon SH, Lee K, Kim YJ, Lee SJ, Nam TW, Ko G Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice. Nature Microbiology. 2021. PubMed: 33820962Preclinical (animal / cell)
- 5.Zhang J, Ni Y, Qian L, Fang Q, Zheng T, Zhang M, Gao Q, Zhang Y, Ni J, Hou X, Bao Y, Kovatcheva-Datchary P, Xu A, Li H, Panagiotou G, Jia W Decreased Abundance of Akkermansia muciniphila Leads to the Impairment of Insulin Secretion and Glucose Homeostasis in Lean Type 2 Diabetes. Advanced Science. 2021. PubMed: 34085773Human observational
- 6.Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM, de Barsy M, Loumaye A, Hermans MP, Thissen JP, de Vos WM, Cani PD Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine. 2019. PubMed: 31263284Clinical (RCT / meta-analysis)
- 7.Zhang Y, Liu R, Chen Y, Cao Z, Liu C, Bao R, Wang Y, Huang S, Pan S, Qin L, Wang J, Ning G, Wang W Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut. Cell Metabolism. 2025. PubMed: 39879980Clinical (RCT / meta-analysis)
- 8.Suenaert P, Segers A, Rymenans L, Devroye H, Moll JM, Cani PD, de Vos WM Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels. Gut Microbes. 2026. PubMed: 42343233Clinical (RCT / meta-analysis)
- 9.Mo C, Lou X, Xue J, Shi Z, Zhao Y, Wang F, Chen G The influence of Akkermansia muciniphila on intestinal barrier function. Gut Pathogens. 2024. PubMed: 39097746Preclinical (animal / cell)
- 10.Liu E, Ji X, Zhou K Akkermansia muciniphila for the Prevention of Type 2 Diabetes and Obesity: A Meta-Analysis of Animal Studies. Nutrients. 2024. PubMed: 39458436Preclinical (animal / cell)
- 11.Si J, Kang H, You HJ, Ko G Revisiting the role of Akkermansia muciniphila as a therapeutic bacterium. Gut Microbes. 2022. PubMed: 35613313Preclinical (animal / cell)
- 12.Mruk-Mazurkiewicz H, Kulaszynska M, Czarnecka W, Podkowka A, Ekstedt N, Zawodny P, Wierzbicka-Wos A, Marlicz W, Skupin B, Stachowska E, Loniewski I, Skonieczna-Zydecka K Insights into the Mechanisms of Action of Akkermansia muciniphila in the Treatment of Non-Communicable Diseases. Nutrients. 2024. PubMed: 38892628Preclinical (animal / cell)
- 13.EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal. 2021. PubMed: 34484452Clinical (RCT / meta-analysis)